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THE EFFECT OF A PRIOR AUTHORIZATION PROGRAM
FOR PROTON-PUMP INHIBITORS ON MEDICATION
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OBJECTIVES: To evaluate the effect of a prior authorization (PA) requirement on 
medication persistence in the elderly following implementation of a step therapy 
program for proton-pump inhibitors (PPI) in the Military Health System. METHODS:
Our study population comprised 33,226 TRICARE beneﬁ ciaries q 65 years old with
a PPI prescription between October 24, 2007 and January 31, 2008. The PA required
patients without a PPI prescription in the last 180 days to receive a trial of the pre-
ferred product (omeprazole or esomeprazole) before receiving another PPI. The study 
cohort (n  15,294) included patients affected by the PA requirement; the reference 
cohort (n  17,932) was not affected because patients received an initial ﬁ ll for the 
preferred product. Medication persistence was measured as 1) proportion of days 
covered (PDC) with persistence deﬁ ned as q 80% of days covered, and (2) time to 
ﬁ rst gap  30 days following initiation. Differences in medication persistence between 
cohorts were detected using logistic regression and a proportional hazards model,
adjusted for age, gender, and type of pharmacy (community vs. mail order). RESULTS:
In the 6 months following initiation of PPI treatment, 46% of study subjects were not
persistent (PDC  80%), while 77% experienced a gap in treatment  30 days. Expo-
sure to the PA requirement decreased the odds of being persistent with treatment at 
6 months by 39% (OR 0.61; 95% CI 0.58¨C0.64) and increased the risk of experienc-
ing a 30-day gap in treatment by 17% (HR 1.17; 95% CI 1.14¨C1.20). CONCLU-
SIONS: The prior authorization program was associated with lower rates of medication
persistence. Further study should evaluate whether the reduction in persistence had 
an effect on patient clinical outcomes.
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RESPONSIVENESS TO CHANGE AND CLINICALLY RELEVANT 
IMPROVEMENTS OF THE SF-36 QUESTIONNAIRE IN SWEDISH
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
Wahlqvist P, Medin J, Rydén A
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OBJECTIVES: To assess responsiveness to change of the Short Form-36 (SF-36)
questionnaire in patients with gastroesophageal reﬂ ux disease (GERD), and whether 
clinically relevant improvements in symptoms correlate with improvements in the 
SF-36. METHODS: The SF-36 (acute version, 1-week recall, score: 0–100) was used
in a methodological study in 205 Swedish GERD patients before and after 4 weeks’ 
proton pump inhibitor (PPI) treatment. After treatment, patients completed a 7-graded 
Overall Treatment Evaluation (OTE) questionnaire with regard to GERD symptoms,
from which three main OTE response groups were identiﬁ ed (no or small improve-
ment, moderate improvement, large improvement). Responsiveness was assessed by 
calculating effect sizes (ES) for all patients and by OTE response group. Clinically
relevant improvements were assessed by comparing SF-36 changes to Swedish popula-
tion norm values and by investigating SF-36 changes by OTE response group. 
RESULTS: The mean overall before-after PPI treatment change for the Physical Com-
ponent (PC) and Mental Component (MC) scores of the SF-36 were 4.6 and 4.4, 
respectively, and ranged from 5.1 to 18.9 for the eight individual SF-36 dimensions 
(all p  0.001). However, SF-36 scores after treatment were similar to Swedish popula-
tion norm values only in those who reported a large improvement in treatment effect 
on symptoms, according to the OTE. Mean OTE changes and ES consistently increased
with degree of improvement for all eight SF-36 dimensions and the PC and MC scores,
demonstrating an association between clinically relevant improvements in symptoms 
and improvements in SF-36. Overall, ES were moderate to high in patients experienc-
ing a large improvement according to the OTE. CONCLUSIONS: Successful GERD 
treatment, as reported by patients, resulted in both statistically signiﬁ cant and clini-
cally relevant improvements in SF-36 scores. The SF-36 was found to be responsive
to change. Given the methodology used, results should be regarded as applicable only 
in a GERD population.
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OBJECTIVES: To assess responsiveness to change and construct validity of the Work 
Productivity and Activity Impairment questionnaire for gastroesophageal reﬂ ux
disease (WPAI : GERD), a GERD-speciﬁ c adaptation of the Speciﬁ c Health Problem 
version of the WPAI. METHODS: The WPAI : GERD measures GERD-speciﬁ c work
absenteeism, presenteeism (reduced productivity while at work) and impairment in 
regular daily activities other than work during the preceding week. It was completed
by 205 employed Swedish patients before and after 4 weeks’ proton pump inhibitor 
treatment for GERD. Responsiveness was assessed by calculating effect sizes (ES) for
all patients and by response group according to a 7-graded Overall Treatment Evalu-
ation (OTE) questionnaire. Construct validity was assessed by investigating the rela-
tionship between WPAI measures and symptoms, as well as health-related quality of 
life (HRQL). RESULTS: Absenteeism was not included in the analyses due to very 
high variability in the results and the relatively low mean before-after treatment change 
(0.4 hours; 95% CI: 2.4, 3.1). The mean overall before-after treatment change in 
percent reduced productivity was 15.3% for presenteeism (from 25.5% to 10.2%; 
p  0.001) and 18.3% for impairment in daily activities (from 31.5% to 13.2%;
p  0.001). ES were moderate for the whole study population (presenteeism: 0.67, 
activity impairment: 0.79) and were large in patients experiencing a large improvement 
according to the OTE (presenteeism: 0.98, activity impairment: 1.22). Cross-sectional 
Pearson correlation coefﬁ cients between WPAI variables and symptoms (range: 0.06–
0.67), as well as HRQL (range: 0.19–0.79) supported cross-sectional construct validity
of the WPAI : GERD. Corresponding change score correlations (range for symptoms:
0.17–0.56, range for HRQL: 0.15–0.61) and a descriptive analysis of change in pro-
ductivity by change in heartburn severity also supported longitudinal construct valid-
ity. CONCLUSIONS: Results indicated that the WPAI : GERD measures of presenteeism 
and activity impairment are responsive to change. Cross-sectional, as well as longitu-
dinal, construct validity of the measures was conﬁ rmed.
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ADULT CANADIANS SUFFERING FROM ACID RELATED
DISEASES: PATIENT REPORTED ATTITUDES, PERCEPTIONS, 
AND IMPACT ON THEIR LIFE
Beamer B, Ciobanu A, Liovas A
AstraZeneca, Mississauga, ON, Canada
OBJECTIVES: To understand patient attitudes and perceptions towards acid related 
diseases (ARD). Furthermore to reveal the degree to which ARD affect patient lives,
and uncover their level of satisfaction with prescription medicines. METHODS: On 
line Canadians 18 years were solicited by email by a national interactive research 
organization. Those who reported a diagnosis of stomach ulcer, duodenal ulcer,
heartburn, acid reﬂ ux/GERD/reﬂ ux esophagitis, Irritable Bowel Syndrome (IBS) or 
dyspepsia/stomach pain, and who have taken prescription medicines for at least one 
month were directed to an on line interactive English or French survey instrument 
from July–August 2007. RESULTS: A total of 1033 ARD patients responded(East 
106,Quebec 260,Ontario 364,West 303). The following conditions were reported: 
stomach ulcer (64); duodenal ulcer (20); heartburn (219); Acid Reﬂ ux/GERD (647); 
Dyspepsia (80); IBS (7). A 2-year average delay was reported before talking with their
physicians about their symptoms. They experience numerous troublesome symptoms
prior to taking medication including heartburn, acidic taste, stomach pain, indigestion,
chest pain, and sleeping problems. Prior to seeking care and medication for these 
symptoms, four in ten reported they felt tired, worn out and were unable to sleep.
Nearly one in ten report missing work. Patients make changes to their diet, social,
work and daily activities to compensate for their conditions. 80% experienced at least 
one somewhat severe or severe symptom prior to treatment, while only 21% did post
treatment. 45% of patients were referred to a specialist with an average wait time
over 12 weeks. Of those referred, 47% underwent an endoscopy. CONCLUSIONS:
Canadians suffering from ARD experience numerous troublesome symptoms that 
negatively impact their quality of life, including missing work, yet on average they
wait two years before seeking help from their physician. Nearly one half are referred 
to specialists and about half of these receive an endoscopy.
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FACTORS INFLUENCING GASTROESOPHAGEAL REFLUX
DISEASE OUTPATIENTS’ CHOICES TO ACCESS DIFFERENT TIERS
OF MEDICAL FACILITIES: THE PRELIMINARY STUDY OF A
DISCRETE CHOICE EXPERIMENT
Tseng JH1, Chen LC1, Kuo C2, Lu C1
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OBJECTIVES: Taiwan’s single payer national health insurance system provides gener-
ous coverage and patients’ full freedom to access different tiers of medical facilities. 
Government’s attempt to divert outpatient care utilisation into primary care by largely 
increasing co-payment only showed limited effects. To determine the relative impor-
tance of factors (attributes) associated with patients’ choices of accessing different tiers
of medical facilities, we conducted a qualitative study on outpatients with gastro-
esophageal reﬂ ux disease (GERD), who generally do not need aggressive treatment. 
METHODS: Focus groups were conducted on outpatients with GERD from different 
tiers of medical facilities in Southern Taiwan. RESULTS: Seven focus groups were held
in medical centers (2), regional hospitals (2), physician clinics (2), and local community
(1), recruiting 35 participants from cities and an off-shore island. Reputation of 
doctors and scale of medical facilities are the highest priorities and unanimous con-
siderations of all participants. Distance (transportation convenience) is also an impor-
tant attribute for accessing medical care. Information sources for making decision
includes consultation with relatives and friends, searching internet information, or 
rank of hospitals and doctors from media. Participants generally thought the current
out-of-pocket payment (OPP) is expensive, especially when accessing medical centers,
but they still preferred and felt worthy to visit higher tiers of medical facilities due to 
